Evidence map›Paper›PMID 34680197›Full record

ArticleCancers2021

Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis.

Hannah C Puhr, Thorsten J Reiter, Mohamed El-Mahrouk, Lena Saliternig, Peter Wolf, Maximilian J Mair, Ariane Steindl, Matthias Paireder, Reza Asari, Sebastian F Schoppmann and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. The application of continuous enteral nutrition during sequential chemoradiotherapy and immunotherapy in patients with esophageal cancer: a retrospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Hannah C PuhrDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Thorsten J ReiterDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Mohamed El-MahroukDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Lena SaliternigDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Peter WolfDepartment of Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, 1090 Vienna, Austria.
Maximilian J MairDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-6537-3874
Ariane SteindlDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-5839-8301
Matthias PairederComprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-7119-8454
Reza AsariComprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Sebastian F SchoppmannComprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
Anna S BerghoffDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Matthias PreusserDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.
Aysegül Ilhan-MutluDepartment of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-8291-0873
Comprehensive Cancer Center Vienna · ATMedical University of Vienna · AT

Funding

Medical University of Vienna n.a.
6 · The paper itself

Abstract

introductionAs thyroid hormones modulate proliferative pathways it is surmised that they can be associated with cancer development. Since the potential association of gastroesophageal cancer and thyroid disorders has not been addressed so far, the aim of this study was to investigate the association of thyroid hormone parameters with the outcome of these patients, so novel prognostic and even potentially therapeutic markers can be defined. MATERIAL AND

methodsClinical and endocrinological parameters of patients with resectable gastroesophageal cancer treated between 1990 and 2018 at the Vienna General Hospital, Austria, including history of endocrinological disorders and laboratory analyses of thyroid hormones at first cancer diagnosis were investigated and correlated with the overall survival (OS).

resultsIn a total of 865 patients, a tendency towards prolonged OS in hypothyroid patients (euthyroid,

conclusionsThyroid disorders and their therapeutic interventions might be associated with the OS in patients with resectable gastroesophageal cancer. As data on the correlation of these parameters is scarce, this study proposes an important impulse for further analyses concerning the association of thyroid hormones with the outcome in patients with gastroesophageal tumors.

Indexed as

esophageal neoplasmsgastrointestinal neoplasmsstomach neoplasmsthyroid diseasesthyroid gland

Identifiers

PMID34680197
PMCPMC8534173
OpenAlexW3164658026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.